Success stories

On this page, you can read about past #EuroTestWeek Success Stories and also past Evaluation Reports.

Success Stories

Read about testing initiatives that took place across Europe to encourage increased efforts for HIV and hepatitis testing and awareness of the benefits of earlier testing.

Want to be featured as a #EuroTestWeek Success Story?

We encourage you to share your story to help others learn from your experiences. You can submit your Success Story to us by completing this template and sending it to eurotest.rigshospitalet@regionh.dk.

You can also share your own success stories by posting your activities, materials, pictures and more on social media. Be sure to tag our accounts, @EuroTestWeek on Facebook and @HIVheptestweek on Twitter use our hashtags #Eurotestweek and #TestTreatPrevent.

2017

Evaluation Report 2019

Read the full evaluation report for the 2019 Spring ETW here or the one page summary.

Past Evaluation Reports

2018
- Spring ETW pilot, report and one page summary
- November ETW, report and one page summary
2017, report and one page summary
2016, report and one page summary.
2015, report and one page summary
2014
2013

EuroTEST Working Together for Optimal Testing and Earlier Care

The contents of this website are © The EuroTEST initiative

Sponsorship statement: The EuroTEST initiative is governed by an independent steering committee. The Coordinating Centre is at CHIP, RegionH, Copenhagen, and the political secretariat at the EATG. The conditions of funding the initiative are approved by the Steering Committee. Industry sponsors are invited to quarterly updates but do not participate in the Steering Committee.

Financial support of the EuroTEST initiative provided by: Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Danish National Research Foundation (grant 126), European Commission under the 3rd and 2nd Health Programmes, European Centre for Disease Prevention and Control (ECDC), Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, Swedish Research Council, ViiV Healthcare and Tibotec.